Development and evaluation of a multiplex test for the detection of atypical bacterial DNA in community-acquired pneumonia during childhood  by Carrillo, J.A. et al.
Development and evaluation of a multiplex test for the detection
of atypical bacterial DNA in community-acquired pneumonia during
childhood
J. A. Carrillo1, J. Gutie´rrez2, F. Garcı´a3, A. Mun˜oz3, E. Villegas2, J. Rojas1, A. Sorlo´zano2 and A. Rojas1
1) Laboratory Vircell, Santa Fe, Granada, 2) Departamento de Microbiologı´a, Facultad de Medicina, Universidad de Granada, Granada and
3) Departamento de Pediatrı´a, Hospital Universitario San Cecilio, Granada, Spain
Abstract
An incorrect or late diagnosis can lead to an increase in the morbidity and mortality caused by pneumonia, and the availability of a rapid
and accurate microbiological test to verify the aetiology is imperative. This study evaluated a molecular test for the identiﬁcation of the
bacterial cause of atypical community-acquired pneumonia (ACAP). Fifty-four children with pneumonia were studied using bacteriologi-
cal cultures, Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneumoniae and Legionella spp. serology, and Streptococcus pneumo-
niae and Legionella antigens. Simultaneously, the presence of bacterial and fungal DNA was tested for in respiratory secretion samples
using the Vircell SL kit, including multiplex PCR and amplicon detection by means of line blots. There were 14 cases of ACAP caused
by M. pneumoniae, with positive kit results for 13 of them, and two cases of Q-fever, with negative kit results for Coxiella burnetii. The
test was negative in the remaining 38 cases (one staphylococcal pneumonia, 20 Streptococcus pneumoniae pneumonias, and 17 probable
viral pneumonias). The sensitivity of the test for the detection of M. pneumoniae was 92.8% and the speciﬁcity was 100%. The Vircell SL
kit allows detection of M. pneumoniae DNA in respiratory secretion samples from children with ACAP.
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Introduction
Community-acquired pneumonia (CAP) is associated with a
high morbidity. Its initial treatment, which is currently empir-
ical, has a decisive inﬂuence on the prognosis. The incidence
and the clinical relevance of the microorganisms considered
to be responsible for the disease, and designated ‘atypical’
(Mycoplasma pneumoniae, Coxiella burnetii, Chlamydophila pneu-
moniae, and Legionella spp.), are controversial [1–3].
Primary infection with C. pneumoniae is frequent in chil-
dren, increases in frequency with age, and is considered to
represent c.10% of all CAPs [4]. The detection of the disease
is hampered by the high prevalence of anti-C. pneumoniae
IgG in adults, repeated asymptomatic infections, and the
absence of IgM in some cases of primary infection [5]. The
diagnosis of M. pneumoniae infection is similarly problematic:
the culture is not reliable [6], there is a high prevalence of
anti-M. pneumoniae IgG in adults, and IgM can be absent in
some primary infection cases [7].
Most cases of Legionella pneumonia (85%) are caused by
Legionella pneumophila [8], which is diagnosed by culture,
immunoﬂuorescence, or serology. Culture requires approxi-
mately 2 weeks, and false-negative results are frequent.
Immunoﬂuorescence on sputum is fast and speciﬁc but has
low sensitivity [9]. Serological tests have a sensitivity of
80%, but the diagnosis is delayed, and false-positive results
are obtained when there is infection with other bacteria
[10]. Moreover, seroconversion can be absent in Legionella
infections diagnosed by other methods [11]. Other short-
comings are that a negative serology result in the acute
phase does not rule out infection, that a positive result in
two consecutive sera without seroconversion is not a reli-
able diagnostic criterion, and that the sensitivity is limited if
serum is obtained too early in the convalescence phase
[12].
Available tests for the detection of Legionella antigen
in urine have a sensitivity of 60–85%, but mainly reveal
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infections with L. pneumophila of serogroup 1 [13]. Finally,
antigenuria can persist for many months, and must therefore
be interpreted with caution, especially in patients with a
possible history of infection with this pathogen [12].
Coxiella burnetii causes Q-fever and chronic endocarditis.
Rapid diagnosis of infection with this bacterium can markedly
reduce its severity [14]. Serological tests are not useful for
detecting infection in an early phase, when antibodies cannot
be detected, and it is difﬁcult to discriminate between cur-
rent and past infections, owing to the presence of the corre-
sponding IgG in the healthy population [15].
The emergence of new molecular techniques has consid-
erably enhanced the possibility of accurate diagnosis of
CAP [16–18]. Vircell SL (Santa Fe, Granada, Spain) has
developed a kit (not yet commercially available) to detect
C. pneumoniae, M. pneumoniae, Coxiella burnetii, the genus
Legionella and L. pneumophila in respiratory tract samples
using PCR and line blot. This study prospectively analysed
the diagnostic capacity of this procedure in clinical samples
from children with pneumonia and contaminated respiratory
secretions. The aim of the study was to test the perfor-
mance of the kit.
Materials and Methods
Human samples
Between January 2006 and April 2007, we studied 54 chil-
dren (<1–13 years old; 32 males, 22 females) referred to the
San Cecilio University Hospital in Granada on the basis of
clinical and radiological suspicion of CAP (characterized by
the presence of newly evident inﬁltrates on chest X-rays
with suggestive clinical and analytical data, cough, purulent
expectoration (in older patients), fever, pleuritic chest pain
and/or leukocytosis). Patients with possible nosocomial pneu-
monia and immunodepressed patients were excluded.
Patients diagnosed with CAP had their complete clinical his-
tory recorded, and underwent physical examination, including
chest X-rays; basic laboratory tests were performed. Antibi-
otic treatment was given according to criteria established
in consensus documents [19,20]. Age, sex and associated
morbidity factors were systematically recorded for all
patients, following appropriate clinical, analytical, functional
and pathological criteria. Radiological signs were categorized
as lobular or multilobular, and the presence of pleural
effusion was recorded. In hospitalized patients, studies
included blood cultures, Gram staining and culture of sputum
(when there was expectoration), culture of pleural liquid
(when there was effusion), and a search for antigens of Strep-
tococcus pneumoniae and Legionella in urine.
CAP aetiology was attributed to atypical bacteria if the
corresponding IgG titres increased four-fold between sero-
logical determination in the acute phase and a second deter-
mination in the convalescence phase (separated by an
average interval of 2 weeks) and if speciﬁc IgM or Legionella
spp. antigen was detected in urine in the acute phase (Binax
NOW, Leti, Spain). ELISA (Vircell SL) was used to detect
anti-M. pneumoniae IgG and IgM, and indirect immunoﬂuores-
cence (Vircell SL) to detect anti-Coxiella, anti-C. pneumoniae,
anti-Chlamydophila psittaci and anti-Legionella IgG and IgM, fol-
lowing the manufacturers’ instructions.
Viral pneumonia was suspected when no bacteria respon-
sible for atypical CAP (ACAP) were isolated and no antibodies
induced by these bacteria were detected in patients with com-
patible clinical ﬁndings (lymphocytosis and/or monocytosis,
C-reactive protein <7 lg/L) who failed to respond to
antibiotic treatment in the ﬁrst 48 h [19,20]. Viral cultures
were not performed.
Nasopharyngeal swabs or aspirates of secretions were
obtained from all patients for the detection of C. pneumoniae,
M. pneumoniae, Coxiella burnetii, Legionella genus and L. pneu-
mophila DNA by using the Vircell SL kit. Fifty-ﬁve throat
swabs from asymptomatic adults were also analysed. Samples
were taken using a sterile swab, resuspended in transport
medium for Chlamydia (Vircell SL), and kept at )20C until
DNA extraction.
DNA extraction
The QIAamp DNA blood mini kit (Qiagen, Turn berry Lane
Valencia, CA, USA) was used to extract DNA from all respi-
ratory secretions, and 200-lL samples were processed
according to the manufacturer’s instructions.
DNA was also extracted from bacterial suspensions of
C. pneumoniae, M. pneumoniae, Coxiella burnetii and Legionella
spp., including L. pneumophila (all serotypes), Legionella dumof-
ﬁi, Legionella longbeachae, Legionella jordanis, Legionella gormanii,
Legionella micdadei and Legionella bozemanii (Table 1), all of
which may cause ACAP.
Ten serial dilutions of 5 ng of this DNA were used to
spike the pharyngeal secretion samples from the 55 asymp-
tomatic individuals. Bacterial suspensions (1.28 · 106 CFU/
mL for Legionella species and 5.59 · 106 CFU/mL for M. pneu-
moniae) were diluted into 800 lL of Tris (0.2 M)/EDTA
(0.1 M) (pH 8). Then, SDS (ﬁnal concentration 0.5%) and
proteinase K (ﬁnal concentration 0.1 g/L) were added, and
the solution was incubated at 37C for 4 h. Two phenol
extraction steps were performed with one volume of phenol/
chloroform/isoamyl alcohol (25 : 24 : 1) and one volume of
chloroform/isoamyl alcohol (24 : 1); DNA was precipitated
with two volumes of ethanol and 5 M NaCl. DNA concentra-
474 Clinical Microbiology and Infection, Volume 15 Number 5, May 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 473–480
tion was determined spectrophotometrically at A260 nm, and
DNA was considered to be pure at an A260 nm/A280 nm ratio
of 1.8–2. Extraction was always performed in a biologically
secure laboratory.
This method was also used to extract 50 ng of DNA
from different microorganisms in order to verify the speci-
ﬁcity of the kit. For this purpose, PCR was performed with
DNA from the following pathogens (isolated in our hospital
by reference techniques or from culture collections): Hae-
mophilus inﬂuenzae, Staphylococcus aureus, Staphylococcus epi-
dermidis, Streptococcus pneumoniae, Streptococcus pyogenes,
Streptococcus agalactiae, Streptococcus crista, Enterococcus
faecalis, Acholeplasma oculi, Mycoplasma mycoides, Chlamydo-
phila pecorum, Chlamydophila trachomatis, C. psittaci, Bordetella
pertussis, Bordetella parapertussis, Candida albicans, Aspergillus
fumigatus, Escherichia coli, Mycobacterium tuberculosis, Listeria
monocytogenes, and Neisseria meningitis serogroups A, B,
and C (Table 1).
Vircell SL prototype kit
Multiplex PCR. Five pairs of oligonucleotides (Table 2) were
required to detect the agents of interest. A 383-bp frag-
ment of the 16S rRNA gene was ampliﬁed to detect the
Legionella genus, and a 289-bp fragment of dnaJ to detect
L. pneumophila [21]. Coxiella burnetii was detected by
amplifying a 438-bp fragment of the COM-1 gene [22].
Finally, for detection of M. pneumoniae, a 481-bp fragment
of the P1 gene was ampliﬁed [23], and for detection of
C. pneumoniae, a 350-bp fragment of the major outer
membrane protein gene ompA was ampliﬁed [24]. After
selection of the oligonucleotides, single PCRs were opti-
mized for each microorganism. A pair of oligonucleotides
for the ampliﬁcation of an 817-bp fragment of the
human mitochondrial cytochrome oxidase subunit III gene
was included in the multiplex PCR as an extraction and
ampliﬁcation control.
TABLE 1. Strains used in the assays with the Vircell SL kit
Chlamydophila pneumoniae ATCC VR-1356
Mycoplasma pneumoniae ATCC 15531
Coxiella burnetii ATCC VR-616
Legionella pneumophila serogroup 1 NCTC 11286
L. pneumophila serogroup 1 NCTC 11191
L. pneumophila serogroup 1 NCTC 11231
L. pneumophila serogroup 1 NCTC 11286
L. pneumophila serogroup 1 NCTC 11424
L. pneumophila serogroup 1 NCTC 12006
L. pneumophila serogroup 1 NCTC 12007
L. pneumophila serogroup 1 NCTC 12008
L. pneumophila serogroup 1 NCTC 12009
L. pneumophila serogroup 1 NCTC 12024
L. pneumophila serogroup 1 NCTC 12098
L. pneumophila serogroup 2 ATCC 33154
L. pneumophila serogroup 3 ATCC 33155
L. pneumophila serogroup 4 ATCC 33156
L. pneumophila serogroup 5 ATCC 33215
L. pneumophila serogroup 6 ATCC 33216
L. pneumophila serogroup 7 NCTC 11984
L. pneumophila serogroup 8 NCTC 11985
L. pneumophila serogroup 9 NCTC 11986
L. pneumophila serogroup 10 NCTC 12000
L. pneumophila serogroup 11 NCTC 12179
L. pneumophila serogroup 12 NCTC 12180
L. pneumophila serogroup 13 NCTC 12181
L. pneumophila serogroup 14 NCTC 12174
Legionella bozemanii NCTC 11368
Legionella dumofﬁi NCTC 11370
Legionella gormanii NCTC 11401
Legionella jordanis NCTC 11533
Legionella longbeachae NCTC 11477
Legionella micdadei NCTC 11371
Haemophilus inﬂuenzae Clinical isolate
Staphylococcus aureus DSM 13661
Streptococcus pyogenes Clinical isolate
Streptococcus agalactiae Clinical isolate
Streptococcus pneumoniae ATCC 49619
Streptococcus epidermidis Clinical isolate
Streptococcus crista Clinical isolate
Enterococcus faecalis Clinical isolate
Acholeplasma oculi Kindly provided by M. Duran
(LCSA, Santa Fe, Granada)
Mycoplasma mycoides Kindly provided by M. Duran
(LCSA, Santa Fe, Granada)
Chlamydophila pecorum Kindly provided by M. Duran
(LCSA, Santa Fe, Granada)
Chlamydophila trachomatis ATCC VR-398B
Chamydophila psittaci ATCC VR-125
Bordetella pertussis ATCC 8467
Bordetella parapertussis NCTC 5952
Candida albicans NCPF 3153
Aspergillus fumigatus ATCC 204305
Escherichia coli NCTC 50001
Mycobacterium tuberculosis NCTC 13144
Listeria monocytogenes NCTC 4885
Neisseria meningitis serogroup A NCTC 10025
N. meningitis serogroup B NCTC 10026
N. meningitis serogroup C NCTC 8554
TABLE 2. Oligonucleotides used for ampliﬁcation by PCR and detection by line blot of a speciﬁc fragment from the
microorganisms included in the test and the internal control
Microorganism
Oligonucleotides for PCR Oligonucleotides for the generation of speciﬁc probes
Oligonucleotide name Sequence Oligonucleotide name Sequence
Legionella genus Lsp-F 5¢-AGCATKGTCTAGCTTGCTAG-3¢ Lsp-int-F 5¢-GGCGAGTGGCGAACGG-3¢
Lsp-R 5¢-ACCTCCCCACTGAAAGTG-3¢ Lsp-int-R 5¢-CAGGCCTTCTTCACACAC-3¢
Legionella pneumophila LPN-F 5¢-CAGGTGGTTTTGGCGGATTTG-3¢ LPN-int-F 5¢-TTTGGTGACGTTTTTGAAG-3¢
LPN-R 5¢-TGTTGAATTCTGACTTGCCC-3¢ LPN-int-R 5¢-CCTGGCATGTTTCACAAG-3¢
Mycoplasma pneumoniae MPN-F 5¢-ACTCGGAGGACAATGGTCAG-3¢ MPN-int-F 5¢-TGATCTCGCCAACGCTC-3¢
MPN-R 5¢-AACCCGGTCTTTTCGTTATCC-3¢ MPN-int-R 5¢-ACCGTCTGCCCGCCATC-3¢
Chlamydophila pneumoniae CPN-F 5¢-CACTAATGCAGGCTTCATTGCC-3¢ CPN-int-F 5¢-CATTTGGGATCGCTTTGATG-3¢
CPN-R 5¢-TGTTTACAGAGAATTGCGATACG-3¢ CPN-int-R 5¢-CAGATCACATTAAGTTCTTC-3¢
Coxiella burnetii CBU-F 5¢-CGCAACAAGAAGAACACGCTC-3¢ CBU-int-F 5¢-CGACCCTGCATCACCAG-3¢
CBU-R 5¢-CTAATTGGAAGTTATCACGCAG-3¢ CBU-int-R 5¢-GGATAGCAGGATTATCC-3¢
Internal control IC-F 5¢-CCACCAATCACATGCCTATCA-3¢ IC-int-F 5¢-CCTCTCAGCCCTCCTAATG-3¢
IC-R 5¢-TAATTGGAAGTTAACGGTACTA-3¢ IC-int-R 5¢-AAATGCCAGTATCAGGCGG-3¢
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To avoid loss of sensitivity in the multiplex PCR, each
sample was simultaneously ampliﬁed with two multiplex PCR
mixtures. The ﬁrst contained oligonucleotides for the ampliﬁ-
cation of M. pneumoniae, C. pneumoniae and Coxiella burnetii
at a ﬁnal concentration in the PCR of 0.5 lM for each pair
of oligonucleotides. The second multiplex PCR was opti-
mized for L. pneumophila, Legionella genus and the human
gene (internal control), with ﬁnal oligonucleotide concentra-
tions of 0.2, 1.2 and 0.25 lM, respectively. PCRs were opti-
mized with respect to the concentration of oligonucleotides,
dNTPs and MgCl2, and the conditions of the PCR pro-
gramme. The oligonucleotides were labelled with biotin at
the 5¢-end to be subsequently detectable by line blot hybrid-
ization. Each PCR was performed in a ﬁnal volume of 25 lL,
using 10 lL of sample. Final concentrations of dNTPs and
MgCl2 were 150 lM and 3 mM, respectively; 1 U of Taq
polymerase (Bioline, S Main St Randolph, MA, USA) was used
per PCR. PCR was carried out in an Eppendorf gradient
thermocycler (Eppendorf, Madrid, Spain) under the following
conditions: a ﬁrst denaturation step at 92C for 2 min, 40
ampliﬁcation cycles (92C, 20 s; 55C, 30 s; 72C, 30 s), and
a ﬁnal extension step at 72C for 3 min.
Probe synthesis. For detection of the microorganisms, speciﬁc
probes were generated by single PCR using the internal oli-
gonucleotide pair of each one of the fragments ampliﬁed in
the multiple PCRs (Table 2). For these PCRs, the six internal
fragments were cloned in a pGEM-T vector (Promega,
Seville, Spain). Each clone was used as template DNA for
ampliﬁcation of the corresponding probe. A ﬁnal volume of
50 lL containing 5 ng of plasmid was used for each PCR.
Final concentrations of dNTPs and MgCl2 were 200 and
3 mM, respectively; 1 U of Taq polymerase (Bioline) was
used per PCR. The PCR was carried out in an Eppendorf
gradient thermocycler (Eppendorf) under the following con-
ditions: a ﬁrst denaturation step at 92C for 1 min, 40 ampli-
ﬁcation cycles (92C, 20 s; 55C, 30 s; 72C, 30 s), and a
ﬁnal extension step at 72C for 3 min. The six PCR products
were used as probes to draw lines on a nylon membrane.
The probes were denatured with NaCl (1.5 M) and
NaOH (1.5 M) for 10 min, neutralized with Tris-HCl (1 M)
and NaCl (1.5 M) (pH 7.4), and ﬁxed on the membrane with
UV light for 2 min.
Line blot hybridization. PCR-generated amplicons were visual-
ized by line blot hybridization. The line blot was formed by a
nylon membrane strip onto which six DNA probes (Table 2)
were placed: ﬁve probes were DNA fragments speciﬁc for
each pathogen under study, and the other probe was a frag-
ment speciﬁc for the ampliﬁed human DNA fragment
(extraction and PCR control). The line blot also included a
control line to react with the conjugate that was subse-
quently used in the colorimetric detection. The seven probes
were dosed (0.3 lL/cm) using a Bio-Dot line dispenser,
model ZX1000 (Bio-Dot, Irvine, CA, USA).
The strip with biotinylated PCR product was hybridized in
a specially designed tray. The two biotinylated PCR products
for each sample were each denatured by adding 20 lL of
solution (NaOH (0.25 M), NaCl (0.75 M)) to the PCR tube
and incubating them for 10 min at room temperature. Then,
1 mL of hybridization solution was added (N-lauryl sarcosine
(2.4 g/L), SDS (0.02%), 6 · SSC, salmon sperm DNA
(100 mg/L), skimmed milk powder (2%), Tris-HCl (0.2 M),
NaCl (0.3 M) (pH 7.4)) and preheated in the hybridization
tray with the strip and two denatured PCR products. This
mixture was incubated for 1 h at 50C under agitation
(80 r.p.m.) in a hybridization oven. Then, the strip was
washed twice for 10 min at 50C with a stringent wash solu-
tion (0.1 · SSC, SDS (1%)). Finally, colorimetric detection
was performed by incubating with 1 mL of conjugate (strep-
tavidin-peroxidase (Caltag, San Francisco, CA, USA)) dis-
solved (1/4000) in conjugate stabilizer (Vircell SL) for 10 min
under agitation (40 r.p.m.). After two washes with washing
solution (phosphate-buffered saline at pH 7.2, Tween-20
(0.05%)), the strip was incubated with TMB (Neogen Corp.,
Lansing, MI, USA) for 5 min to visualize the signal. After
washing of the strip with water, results were interpreted
using an interpretation card.
Results
In preliminary assays using the Vircell SL kit with a multiplex
PCR, a loss of sensitivity was found with a mix of the six
pairs of primers. Therefore, the multiplex PCR was opti-
mized by testing different combinations and concentrations
of primers and different PCR conditions to avoid this loss of
sensitivity. The assay results suggested the preparation of
two PCR mixes, one for M. pneumoniae, C. pneumoniae and
Coxiella burnetii, and the other for L. pneumophila, genus Legio-
nella and the internal ampliﬁcation control, at the concentra-
tions shown in Materials and Methods. With these
combinations of oligonucleotides, no loss of sensitivity was
detected with respect to the individual PCRs.
Among the 54 children in the study, 14 (26%) had ACAP
due to M. pneumoniae, based on serology, with two showing
IgM in the ﬁrst serum sample. In the other 12 cases, a sec-
ond serum sample was required to observe seroconversion
of IgM and IgG, delaying the diagnosis. A further two chil-
dren (3.7%) had Q-fever, based on serology, one (1.9%) had
476 Clinical Microbiology and Infection, Volume 15 Number 5, May 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 473–480
S. aureus pneumonia and 20 (37%) had Streptococcus pneumo-
niae pneumonia, based on culture and/or on antigen testing,
and viral CAP was suspected in the remaining 17 patients
(31%). Vircell SL kit results were interpreted using the read-
ing card designed for the test (Fig. 1b).
Patient samples
For both children with Q-fever, the Vircell SL test result was
negative for Coxiella burnetii, and for all of those with ACAP
due to M. pneumoniae, except one, the Vircell SL test results
were positive. The test result was negative in the remaining
cases (one S. aureus pneumonia, 20 Streptococcus pneumoniae
pneumonias and 17 viral CAPs). No positive results were
obtained for C. pneumoniae and Legionella spp. using the Vir-
cell SL kit. Globally, therefore, the kit yielded 13 (24%) posi-
tive results for M. pneumoniae in this population of children
with CAP. Line blots were clearly visible and easily inter-
preted using the reading card. The absence of PCR inhibitors
was veriﬁed in all cases, as an intense signal was obtained for
the DNA extraction and PCR control in all samples. Finally,
the test sensitivity for the detection of M. pneumoniae was
92.8% and the speciﬁcity was 100%.
DNA was also extracted from serum from the two
patients who were positive for Coxiella burnetii by serology;
Vircell SL test results were negative for Coxiella burnetii in
both cases.
Samples from asymptomatic individuals
Test speciﬁcity was assessed by performing the Vircell SL
test with the 55 respiratory tract samples from asymptom-
atic individuals. None of these samples yielded a positive
signal.
Analytical sensitivity studies were performed with artiﬁcial
samples generated with serially diluted puriﬁed DNA of the
microorganisms to be detected. A speciﬁc hybridization was
obtained for each, with no signal observed in the remaining
lines. A single intense signal was seen in the reaction, extrac-
tion and PCR controls (Fig. 1a). The limit of detection was
established by performing PCRs on replicas of dilutions in
triplicate, with this limit being considered to be the lowest
level at which all three dilutions gave a positive result. The
limit of detection was 5 pg of DNA for C. pneumoniae, Coxiel-
la burnetii and the genus Legionella, and 0.5 pg for L. pneumo-
phila and M. pneumoniae. Because we selected highly
conserved regions of the mip gene among different L. pneumo-
phila serogroups and of the 16S rRNA gene in the genus Leg-
ionella, no differences in sensitivity were observed among the
species.
The reproducibility of the test was evaluated by using three
different serial dilutions of each microorganism in intra-assay
and inter-assay experiments carried out by two examiners.
Identical dilution limits were obtained in these experiments.
The technique took 3.5 h to complete: 1.5 h for the PCR, and
2 h for the line blot development. With the primer combina-
tions selected for the multiplex PCRs, their reproducibility
was the same as found for the individual PCRs.
Other speciﬁcity studies
The absence of cross-reactions was assessed by performing
the test with 50 ng of DNA of each of the 23 microorganisms
described above. No false-positive results were obtained.
Discussion
This study evaluated a multiplex molecular test to determine
the bacterial cause of ACAP in 54 children (14 due to
M. pneumoniae, two cases of Q-fever, one staphylococcal
(a) (b)
FIG. 1. Hybridization results for samples positive for each microorganism of interest in the following order: 1, negative PCR control; 2, positive
PCR control; 3, Mycoplasma pneumoniae; 4, Coxiella burnetii; 5, Chlamydophila pneumoniae; 6, Legionella sp; 7, Legionella pneumophila. (b) Reading
card for the interpretation of results.
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pneumonia, 20 Streptococcus pneumoniae pneumonias, and 17
probable viral pneumonias). The test identiﬁed 13 cases of
ACAP due to M. pneumoniae, and was negative in the
remaining 41 cases.
Among earlier molecular biology approaches, DNA
hybridization techniques with labelled probes and polymor-
phism analyses of restriction fragments were used to detect
DNA of atypical respiratory tract bacteria [25]. However,
techniques based on nucleic acid ampliﬁcation should offer
faster and improved pathogen detection, allowing earlier
diagnosis and treatment. Over the past few years, numerous
PCR tests have been optimized for the detection of different
pathogens implicated in pneumonia, e.g. C. pneumoniae [26],
M. pneumoniae [27], Coxiella burnetii [22], L. pneumophila, and
the genus Legionella [21]. In the design of these PCRs,
authors used primers for speciﬁc genes of the bacteria of
interest, to avoid false-positive results. These are commonly
designed for genes of membrane-speciﬁc antigens, e.g. the P1
gene for M. pneumoniae [23,24] or the mip gene for L. pneu-
mophila [9]. Ribosomal RNA genes or intergenic spacers are
also considered as PCR targets, mostly for the design of
genus-speciﬁc primers [21].
Although there are numerous single PCR systems for
microorganism detection, multiplex PCR protocols are less
common, despite the savings that they offer in time and cost.
Multiplex PCR systems are available that include some of the
microorganisms investigated in the present study, e.g.
M. pneumoniae and C. pneumoniae [28], C. pneumoniae, C. psit-
taci and M. pneumoniae [29], C. pneumoniae, M. pneumoniae
and L. pneumophila [30], and C. pneumoniae, M. pneumoniae
and genus Legionella [24]. Others include M. pneumoniae and
C. pneumoniae with Streptococcus pneumoniae and H. inﬂuenzae
[23]. In these systems, results are sometimes interpreted by
using agarose gels or ELISA. The test evaluated in this article
offers a direct visual reading, adding to its value in the clinical
setting.
The proposed test showed excellent performance in the
detection of ACAP caused by M. pneumoniae. In one patient
with positive serology for M. pneumoniae, no signal was
obtained with the Vircell SL kit, and no PCR inhibitors were
detected in this sample. This false-negative result can be
attributed to a more advanced phase of the disease. In this
case, seroconversion was not accompanied by the presence
of bacterial DNA in the respiratory tract sample. This factor
should be taken into account in the clinical interpretation of
results.
Serology gave positive results for Coxiella burnetii in the
two samples studied, but a negative result was obtained with
the Vircell SL kit in both respiratory tract samples. In gen-
eral, Coxiella burnetii has been detected by PCR with DNA
extracts of serum samples [22,31]. Therefore, PCR was also
performed with serum samples that were positive for Coxiella
burnetii by indirect immunoﬂuorescence, yielding negative
results in both cases. False-negative results are frequently
reported in the detection of Coxiella burnetii using PCR with
serum samples. Thus, Zhang et al. [22] obtained 14.8% false-
negative results in a nested PCR with speciﬁc plasmids of
Coxiella burnetii in serum samples, and Fenollar et al. [32]
obtained only 64% sensitivity with sera of patients with
endocarditis or vascular infection.
Fournier and Raoult [31] found the sensitivity to be low
(26%) in samples collected during the ﬁrst 2 weeks after
onset of the disease, when antibodies could not yet be
detected. The sensitivity was even lower (5%) in samples
drawn after the ﬁrst 2 weeks, when antibodies could be
detected [30]. Low PCR sensitivity with serum samples is
due to the scant amount of DNA present, limiting the detec-
tion of Coxiella burnetii by PCR.
Our serological study suggests that the two samples posi-
tive for Coxiella burnetii were from patients who had con-
tracted the disease more than 2 weeks earlier, when DNA
detection in serum has the lowest diagnostic value [31]. A
larger number of Coxiella burnetii-positive serum samples are
required to assess the validity of the technique. Neverthe-
less, it is possible that this test is not effective in Q-fever
patients, who are often asymptomatic and are only diag-
nosed using serology. In these cases, it is possible that a
higher diagnostic accuracy could be obtained at the onset of
the disease by analysing peripheral blood or lower respira-
tory tract samples.
We believe that this new PCR kit offers a clear advantage
over serological techniques for the diagnosis of ACAP
caused by M. pneumoniae, cases in which there are frequent
losses of the second serum sample, especially when there is
clinical improvement, meaning that the causal agent often
remains unknown. So, in adults, owing to the high seropreva-
lence of IgG [33], re-infection with any of the microorgan-
isms produces elevated titres of IgG in the ﬁrst sample,
preventing demonstration of seroconversion. By contrast,
direct diagnosis using the Vircell SL kit allows immediate and
speciﬁc detection of the pathogen in the acute phase of the
disease in a single sample.
In conclusion, a highly reproducible technique has been
optimized. The multiplex PCR test, in conjunction with a line
blot used in the Vircell SL kit, has high sensitivity for the
detection of M. pneumoniae in upper respiratory tract secre-
tions from patients with ACAP. There were no false-positive
results when respiratory samples from asymptomatic individ-
uals were analysed, and no cross-reactions were detected
for the microorganisms studied.
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